All In MedTech

Device Trial Radar · NCT04185961

Pilot Study to Determine the Optimal Negative Pressure for Non-invasive Breast Augmentation in Women

A Double-blind Pilot Study to Determine the Optimal Negative Pressure of EVERA-RAPHA for Non-invasive Breast Augmentation in Women

Last checked: Nov 20, 2026Latest source record: May 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jan 6, 2020

Primary completion

Mar 30, 2020

Study completion Apr 6, 2020

Sponsor

Lead sponsor
Seoul National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 4, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 20 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Aim is to investigate optimum pressure and evaluate safety and effectiveness of EVERA-RAPHA for breast augmentation

Conditions

  • Breast Hypoplasia

Interventions

  • EVERA-RAPHA with 60mmHGDevice

    Apply EVERA-RAPHA with 60mmHG for 4weeks

  • EVERA-RAPHA with 100mmHGDevice

    Apply EVERA-RAPHA with 100mmHG for 4weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in the breast volume between before and after 4 weeks in test group 1 and test group 2 respectively.Time frame: Baseline and after 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National Univ. Bundang Hospital

    Seongnam-si, Bundang,Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.